IMPACT THERAP-B (07630) Opens Over 3% Higher as Latest Clinical Data for Three Pipeline Drugs Including IMP4297 Debut at ESMO 2026 Congress

Stock News10-26

IMPACT THERAP-B (07630) opened more than 3% higher, rising 3.55% to HK$10.78 as of press time, with a turnover of HK$306,200.

On the news front, on October 23, IMPACT THERAP-B announced that the latest clinical data for its pipeline drugs senaparib (IMP4297), IMP1734 (also known as EIK1003) and IMP1707 (also known as EIK1004) were presented as posters at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, from October 23 to 27, 2026.

Dr. Cai Suixiong, Chief Executive Officer of the company, stated: "We are delighted that the latest clinical data for senaparib as well as the two novel selective PARP1 inhibitors IMP1734 and IMP1707 have been published at the 2026 ESMO Congress. These data further demonstrate the steady progress of our synthetic lethality research and development pipeline. Looking ahead, we will continue to advance differentiated precision anti-cancer therapies, accelerate the global clinical development of our products, and deepen our collaboration with Eikon Therapeutics, striving to bring tangible clinical benefits to cancer patients worldwide."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment